Biography

Prof. Wang obtained his doctor degree from the Chinese Academy of Science. Now he is a research scientist in the Department of Oral Maxillofacial-Head& Neck Oncology and a master's supervisor. As the person in charge, he has successively presided over 5 National Natural Science Foundation projects and 1 key science and technology support project of Shanghai Municipal Science and Technology Commission, who was also supported by the Double Hundred Talents Program of Shanghai Jiao Tong University School of Medicine. He has published 17 SCI papers as the first author or corresponding author.

The research group guided by Prof. Wang give full play to the integrative advantages of medical and pharmaceutical expertise, focus on the research of common molecular mechanisms in tumors and metabolic diseases, confirm drug targets and develop drugs.

(1) Aiming at the high expression oncoprotein EZH2 in oral tumors, they designed and developed inhibitors that can directly target EZH2 degradation. Pharmacological studies on these drugs revealed a new EZH2 degradation signal pathway, providing a new idea for the research of new EZH2 inhibitors.

(2) To study the ability of KDM6A to regulate circadian rhythm and macrophage differentiation, they verify that KDM6A is an innovative target for regulating energy storage and consumption, and obtain a Chinese invention patent. (Adv Sci, IF=17.521; Cell Death Differ, IF=12.067)

(3) In view of the specific neuro tumor interaction regulation phenomenon in oral squamous cell carcinoma patients, they found that the inhibition of nociceptor nerves can reduce the survival of tumor cells under starvation therapy. Since these drugs are both in clinical use, this study provides an important research basis for the clinical use of the combination of the two drugs, and has attracted close attention from researchers in the broad field.